Evidence map›Paper›PMID 41491441›Full record

ArticleBMC cancer2026

A radiomics and machine learning-based method for dynamic assessment of tumor burden after neoadjuvant therapy in esophageal cancer.

Yan Zhu, Tingting Chen, Shuangqing Chen, Genji Bai, Zhenzhong Zhang

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan ZhuDepartment of Radiology, The Affiliated Huaian No.1 Hospital of Nanjing Medical University, Huai'an, PR China.
Tingting ChenDepartment of Radiology, The Affiliated Huai'an Hospital of Yangzhou University, the Fifth People's Hospital of Huai'an, Huai'an, PR China.
Shuangqing ChenDepartment of Radiology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, PR China.
Genji BaiDepartment of Radiology, The Affiliated Huaian No.1 Hospital of Nanjing Medical University, Huai'an, PR China.
Zhenzhong ZhangDepartment of Thoracic Surgery, The Affiliated Huaian No.1 Hospital of Nanjing Medical University, 1 Huanghe Road West, Huai'an, 223001, PR China. zhang_zhenzhong@outlook.com.ORCID http://orcid.org/0000-0001-5235-583X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConventional response evaluation criteria primarily rely on tumor size reduction to assess the efficacy of neoadjuvant therapy (NAT) in esophageal cancer. However, these morphological assessments often fail to capture the underlying biological changes, as some patients achieve substantial pathological response without marked tumor shrinkage. To address this limitation, we introduced the concept of tumor burden (TB), integrating both tumor volume (TV) and tumor regression grade (TRG), and proposed four novel parameters—TV change ratio (TVCR), pre-NAT mean cross-sectional area (Pre-NT MCSA), post-NAT MCSA (Post-NT MCSA), and post-NAT mean cross-sectional TB (Post-NT MCTB)—to better quantify residual disease.

methodsWe conducted a retrospective study of 204 esophageal cancer patients who underwent NAT followed by minimally invasive esophagectomy between September 2019 and September 2024. The relationships between the four novel parameters and resection status were evaluated. Subsequently, a radiomics-based random forest model was developed to predict post-NAT TB (Post-NT TB) from pre- and post-NAT CT images.

resultsAmong the four parameters, only Post-NT MCTB showed a significant association with resection status (p < 0.01), confirming its clinical relevance in reflecting residual TB. The radiomics-based model demonstrated robust predictive performance, achieving a coefficient of determination (R²) of 0.85 in the test set.

conclusionsPost-NT MCTB serves as a clinically relevant indicator of residual TB after NAT, surpassing traditional volume-based assessment. This radiomics-based framework enables dynamic and quantitative evaluation that may assist preoperative planning in esophageal cancer.

Indexed as

Esophageal NeoplasmsMachine LearningNeoadjuvant TherapyTumor BurdenAgedEsophagectomyFemaleHumansMaleMiddle AgedNeoplasm, ResidualRadiomicsRetrospective StudiesTomography, X-Ray ComputedEsophageal squamous cell carcinomaNeoadjuvant therapyRadiomicsTumor burden

Identifiers

PMID41491441
PMCPMC12874719

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.